Glaxosmithkline Biologicals Sa

University of Copenhagen

Msd Italia S.r.l.

Antonella Folgori

Stefano Colloca

Alfredo Nicosia

Stefania Capone

Riccardo Cortese

Armin Lahm

Virginia Ammendola

Rossella Merone

Benjamin Wizel

Peter Johannes Holst

Maria Rosaria Bassi

Anna Morena D'Alise

The invention provides Epstein-Barr Virus antigen polynucleotides, polypeptides and vectors; as well as immunogenic compositions comprising the same. It includes the use of Epstein-Barr Virus antigen constructs to produce vaccines for treating and preventing Epstein-Barr Virus infections and Epstein-Barr Virus-associated diseases, such as multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus.

Epstein-Barr Virus antigen constructs

The present invention relates to isolated polynucleotide and polypeptide sequences derived from novel chimpanzee adenovirus ChAd157, as well as to recombinant polynucleotides, vectors, adenoviruses, cells and compositions comprising said polynucleotide and polypeptide sequences.

Adenovirus polynucleotides and polypeptides

Epstein-barr virus antigen constructs

Simian adenovirus vectors comprising the ChAd-157 fiber protein

The present application provides inter alia a fusion protein comprising a polypeptide wherein the polypeptide consists of a fragment of invariant chain which is operably linked to an antigenic sequence and wherein the fragment of invariant chain consists of a portion of residues 17-97 of SEQ ID NO: 1, wherein the portion comprises at least 5 contiguous residues from residues 77-92 of SEQ ID NO: 1.

Fusion peptides with antigens linked to short fragments of invariant chain(CD74)

The present application relates to novel administration regimens for poxviral vectors comprising nucleic acid constructs encoding antigenic proteins and invariant chains. In particular the use of said poxviral vectors for priming or for boosting an immune response is disclosed.

Poxviral vaccines

The present invention features nucleic acid constructs that can be used as a HCV nucleic acid vaccine, vaccine component, or in the production of a HCV vaccine. Described constructs include those: (1) encoding for a chimeric HCV polypeptide containing a NS3-4A region based on a first HCV strain and an NS3-NS4A-NS4B-NS5A or an NS3-NS4A-NS4B-NS5A-NS5B region based on a second strain; and (2) a chimpanzee based adenovector encoding an HCV polypeptide.

Hepatitis C virus nucleic acid vaccine

Growing community of inventors

Rome, Italy

Antonella Folgori